Nasus Pharma Ltd. NSRX 深 滬
等待開盤 12-13 09:30:00 美东时间
6.80
+0.300
+4.62%
華盛通- 最 高6.80
- 今 開6.655
- 成交量 305股
- 最 低 6.655
- 昨 收 6.50
- 總市值 6160.53万
- 52周最高 9.9899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.90
- 委 比 0.00%
- 總股本 905.96万
- 歷史最高 9.9899
- 量 比 0.64
- 振 幅 2.23%
- 歷史最低 5.90
- 每 手 1
- 風險率 0.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephrine Powder Formulation With Dosing Of First Patient To Treat Anaphylaxis
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today
11-18 21:07
Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced
11-06 21:09
Nasus Pharma Updates Corporate Presentation
Nasus Pharma Ltd. ( ($NSRX) ) has provided an update. On November 3, 2025, Nasu...
11-03 21:25
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Nasus Pharma partners with Aptar to accelerate NS002 development, a needle-free intranasal epinephrine product for anaphylaxis. The collaboration provides proven Unit Dose System technology, regulatory support, and manufacturing capabilities, aiming to speed up FDA and EMA approvals while minimizing risks. NS002 leverages Nasus' proprietary powder-based intranasal technology for rapid drug delivery via the nasal cavity's vascular network, offerin...
10-08 12:04
Nasus Pharma Ltd. Secures Additional Funding from IPO Over-Allotment
Nasus Pharma Ltd. ( ($NSRX) ) just unveiled an announcement. On September 30, 2...
10-01 04:38
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22
Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.
09-29 20:22
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
<p><p align="justify">Nasus Pharma Ltd., a clinical-stage pharmaceutical company developing innovative intranasal products for emergency medical conditions, announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, from 7:00-7:30 a.m. ET. The virtual presentation will be led by Dan Teleman, Chief Executive Officer. The company focuses on intranasal powder products, such as its...
09-02 12:00
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
Nasus Pharma Ltd., a clinical-stage pharmaceutical company, announced it rang the Closing Bell at the New York Stock Exchange, marking a significant milestone in its effort to transform emergency medicine through needle-free, fast-acting intranasal therapies. The company, which specializes in developing proprietary intranasal powder products to address unmet medical needs such as severe allergic reactions and anaphylaxis, celebrated its recent li...
08-26 12:00
一周IPO观察：中慧生物/银诺医药大涨，双登股份招股，奥克斯过讯，Bullish美股上市，Gemini递表
港股IPO观察 截止2025年的第33周，港交所2家上市，1家招股，3家聆讯，8家递表。 当周上市（2家） 研发流感疫苗的生物医药公司 $中慧生物-B(02...
08-18 12:02
